A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Inclusion Criteria: * Histologically or cytologically documented Stage IV non-squamous NSCLC not amenable to curative surgery or radiation. * Participants must have tumors with STK11 or KEAP1 or KRAS mutations. Co-mutations are also allowed. * Participants must have tumors that lack activating epidermal growth factor receptor mutations and ALK fusions. * No prior chemotherapy or any other systemic therapy for metastatic NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, provided that progression has occurred \> 6 months from end of last therapy. * No prior exposure to immune-mediated therapy excluding therapeutic anti-cancer vaccines, within 6 months of randomization. * WHO/ECOG performance status of 0 or 1 at enrollment and randomization. * Minimum life expectancy ≥ 12 weeks at randomization. * At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 target lesion at baseline and can be accurately measured at baseline as ≥ 10 mm in the longest diameter with Computed Tomography (CT)/CT- Positron Emission Tomography or Magnetic Resonance Imaging and that is suitable for accurate repeated measurements as per RECIST 1.1 guidelines. * Adequate organ and bone marrow function. * Negative pregnancy test (urine or serum) for women of child-bearing potential * Female participants must be 1 year post-menopausal, surgically sterile, or using one highly effective form …